Tegavivint for Wilms Tumor

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Wilms Tumor+36 More
Tegavivint - Drug
Eligibility
< 65
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new drug to see if it can stop the growth of cancer cells.

Eligible Conditions
  • Wilms Tumor
  • Colorectal Carcinoma
  • Ovarian Carcinoma
  • Refractory Osteosarcoma
  • Endometrial Carcinoma
  • Melanoma
  • recurrent Ewing's Sarcoma
  • Hepatoblastoma
  • Liver carcinoma
  • Lymphoma, Non-Hodgkin
  • Osteosarcoma
  • Fibromatosis, Aggressive
  • Refractory Ewing Sarcoma
  • Pancreas
  • Neuroblastoma
  • Pancreatic Adenocarcinoma (Ductal Adenocarcinoma)
  • Recurrent Malignant Solid Neoplasm
  • Refractory Hepatoblastoma
  • Refractory Hepatocellular Carcinoma
  • Malignant Neoplasms

Treatment Effectiveness

Study Objectives

8 Primary · 1 Secondary · Reporting Duration: Up to 60 months

Up to 2 days
Area under the drug concentration curve of tegavivint
Clearance of tegavivint
Half-life of tegavivint
Maximum serum concentration of tegavivint
Minimum serum concentration of tegavivint
Up to 28 days
Frequency of dose limiting toxicities of tegavivint
Up to 336 days
Antitumor effects of tegavivint in patients with solid tumors
Up to 60 days
Antitumor effect of tegavivint
Up to 60 months
Frequency of adverse events attributable to tegavivint

Trial Safety

Trial Design

1 Treatment Group

Treatment (tegavivint)
1 of 1
Experimental Treatment

147 Total Participants · 1 Treatment Group

Primary Treatment: Tegavivint · No Placebo Group · Phase 1 & 2

Treatment (tegavivint)Experimental Group · 3 Interventions: X-Ray Imaging, Dual X-ray Absorptiometry, Tegavivint · Intervention Types: Procedure, Procedure, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Dual X-ray Absorptiometry
2019
N/A
~30
Tegavivint
2018
Completed Phase 1
~30

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to 60 months

Who is running the clinical trial?

Children's Oncology GroupLead Sponsor
446 Previous Clinical Trials
234,943 Total Patients Enrolled
29 Trials studying Wilms Tumor
17,879 Patients Enrolled for Wilms Tumor
National Cancer Institute (NCI)NIH
12,991 Previous Clinical Trials
41,298,346 Total Patients Enrolled
54 Trials studying Wilms Tumor
21,409 Patients Enrolled for Wilms Tumor
Sarah B WhittlePrincipal InvestigatorPediatric Early Phase Clinical Trial Network

Eligibility Criteria

Age < 65 · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
Patients with recurrent or refractory solid tumors including non-Hodgkin lymphoma and desmoid tumors are eligible
You have a solid tumor that has relapsed or has not responded to treatment.
You have fully recovered from the acute toxic effects of all prior anti-cancer therapy and must meet the following minimum duration from prior anti-cancer directed therapy prior to enrollment

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 19th, 2021

Last Reviewed: October 10th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.